中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

Regorafenib治疗肝癌的临床研究进展

祁兴顺 贾佳 刘雷 陈辉 柏明 樊代明 韩国宏

引用本文:
Citation:

Regorafenib治疗肝癌的临床研究进展

DOI: 10.3969/j.issn.1001-5256.2014.03.007
详细信息
  • 中图分类号: R735.7

Regorafenib for treatment of hepatocellular carcinoma: an overview of clinical trials

  • 摘要:

    Regorafenib是1种新型的多激酶抑制剂,已被批准用于转移性结肠癌和胃肠道间质瘤的治疗。旨在总结Regorafenib治疗肝癌的临床研究进展。Ⅰ期和Ⅱ期临床试验已证实Regorafenib在肝癌患者中的安全性。Ⅱ期临床试验也显示Regorafenib作为肝癌患者的二线治疗手段可以较好地控制肿瘤的进展。1项正在进行的Ⅲ期随机对照试验将比较Regorafenib与安慰剂之间作为晚期肝癌的二线治疗手段的安全性和有效性。研究分析表明Regorafenib可以有效地控制肝癌进展,有望成为晚期肝癌的二线治疗手段。

     

  • [1]SIROHI B, PHILIP DS, SHRIKHANDE SV.Regorafenib:carving a niche in the crowded therapeutic landscape[J].Expert Rev Anticancer Ther, 2013, 13 (4) :385-393.
    [2]WILHELM SM, DUMAS J, ADNANE L, et al.Regorafenib (BAY73-4506) :a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J].Int J Cancer, 2011, 129 (1) :245-255.
    [3]VILLANUEVA MT.Gastrointestinal cancer:regorafenib, the CORRECT way forward or just another GRIDlock?[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (1) :1.
    [4]GROTHEY A, van CUTSEM E, SOBRERO A, et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) :an international, multicentre, randomised, placebo-controlled, phase 3 trial[J].Lancet, 2013, 381 (9863) :303-312.
    [5]ZAKI K, ASLAM S, EISEN T.Regorafenib (BAY 73-4506) :stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma[J].Curr Oncol Rep, 2013, 15 (2) :91-97.
    [6]DAVIS SL, ECKHARDT SG, MESSERSMITH WA, et al.The development of regorafenib and its current and potential future role in cancer therapy[J].Drugs Today (Barc) , 2013, 49 (2) :105-115.
    [7]DEMETRI GD, REICHARDT P, KANG YK, et al.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) :an international, multicentre, randomised, placebo-controlled, phase 3 trial[J].Lancet, 2013, 381 (9863) :295-302.
    [8]MROSS K, FROST A, STEINBILD S, et al.A phase I dose-escalation study of regorafenib (BAY 73-4506) , an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors[J].Clin Cancer Res, 2012, 18 (9) :2658-2667.
    [9]SUNAKAWA Y, FURUSE J, OKUSAKA T, et al.Regorafenib in Japanese patients with solid tumors:phase I study of safety, efficacy, and pharmacokinetics[J].Invest New Drugs, 2013, 32 (1) :104-112.
    [10]SHIMIZU T, TOLCHER AW, PATNAIK A, et al.Phase I doseescalation study of continuously administered regorafenib (BAY 73-4506) , an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors[J].J Clin Oncol, 2010, 28 (Suppl 15) :3035-2025.
    [11]FINN RS, BLUMENSCHEIN GR, TOLCHER AW, et al.Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC) :Phase I safety and pharmacokinetic (PK) study[J].J Clin Oncol, 2013, 31 (Suppl 4) :300.
    [12]GEORGE S, WANG Q, HEINRICH MC, et al.Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib:a multicenter phase II trial[J].J Clin Oncol, 2012, 30 (19) :2401-2407.
    [13]EISEN T, JOENSUU H, NATHAN PD, et al.Regorafenib for patients with previously untreated metastatic or unresectable renalcell carcinoma:a single-group phase 2 trial[J].Lancet Oncol, 2012, 13 (10) :1055-1062.
    [14]BRUIX J, TAK WY, GASBARRINI A, et al.Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma:Multicentre, open-label, phase II safety study[J].Eur J Cancer, 2013, 49 (16) :3412-3419.
    [15]CHENG AL, FINN RS, KUDO M, et al.Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib:An ongoing randomized, double-blind, phase III trial[J].J Clin Oncol, 2013, 31 (Suppl 15) :4163.
  • 加载中
计量
  • 文章访问数:  3396
  • HTML全文浏览量:  13
  • PDF下载量:  663
  • 被引次数: 0
出版历程
  • 出版日期:  2014-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回